Abstract
The field of oxylipin research has outpaced the development of standards and guidelines. As these signaling lipids gain attention in inflammation, metabolism, and tissue repair, the field must confront a central challenge: many proposed pro-resolving mediators are difficult to measure and interpret. A recent publication by Schebb and colleagues calls for stronger evidence, from analytical detection to endogenous function.